Literature DB >> 11668610

Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.

L D Notarangelo1, P Mella, A Jones, G de Saint Basile, G Savoldi, T Cranston, M Vihinen, R F Schumacher.   

Abstract

During the last 10 years, an increasing number of genes have been identified whose abnormalities account for primary immunodeficiencies, with defects in development and/or function of the immune system. Among them is the JAK3-gene, encoding for a tyrosine kinase that is functionally coupled to cytokine receptors which share the common gamma chain. Defects of this gene cause an autosomal recessive form of severe combined immunodeficiency with almost absent T-cells and functionally defective B-cells (T(-)B(+) SCID). Herewith, we present molecular information on the first 27 unique mutations identified in the JAK3 gene, including clinical data on all of the 23 affected patients reported so far. A variety of mutations scattered throughout all seven functional domains of the protein, and with different functional effects, have been identified. Availability of a molecular screening test, based on amplification of genomic DNA, facilitates the diagnostic approach, and has permitted recognition that JAK3 deficiency may also be associated with atypical clinical and immunological features. Development of a structural model of the JAK3 kinase domain has allowed characterization of the functional effects of the various mutations. Most importantly, molecular analysis at the JAK3 locus results in improved genetic counseling, allows early prenatal diagnosis, and prompts appropriate treatment (currently based on hematopoietic stem cell transplantation) in affected families. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668610     DOI: 10.1002/humu.1188

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  23 in total

Review 1.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 2.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Authors:  Titus J Boggon; Yiqun Li; Paul W Manley; Michael J Eck
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

4.  Genotype, phenotype, and outcomes of nine patients with T-B+NK+ SCID.

Authors:  Grace P Yu; Kari C Nadeau; David R Berk; Geneviève de Saint Basile; Nathalie Lambert; Perrine Knapnougel; Joseph Roberts; Kristina Kavanau; Elizabeth Dunn; E Richard Stiehm; David B Lewis; Dale T Umetsu; Jennifer M Puck; Morton J Cowan
Journal:  Pediatr Transplant       Date:  2011-08-23

Review 5.  The use of structural biology in Janus kinase targeted drug discovery.

Authors:  Nilda L Alicea-Velázquez; Titus J Boggon
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

6.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

7.  Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Authors:  Sigrun R Hofmann; Albert Q Lam; Stephan Frank; Yong-Jie Zhou; Haydeé L Ramos; Yuka Kanno; Davide Agnello; Richard J Youle; John J O'Shea
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 8.  Validating therapeutic targets through human genetics.

Authors:  Robert M Plenge; Edward M Scolnick; David Altshuler
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

Review 9.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

Review 10.  Homing endonucleases: from basics to therapeutic applications.

Authors:  Maria J Marcaida; Inés G Muñoz; Francisco J Blanco; Jesús Prieto; Guillermo Montoya
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.